Genmab Fails To Convince CHMP Of Case For Maintenance Arzerra
The anti-CD20 monoclonal antibody Arzerra (ofatumumab) has not been recommended for the maintenance therapy of relapsed chronic lymphocytic leukemia (CLL), an expanded indication, by the Committee for Medicinal Products for Human Use (CHMP).
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.